

06 AUGUST 2026

ASX RELEASE

BIOSHARES BIOTECH SUMMIT PRESENTATION – TARGETING PANCREATIC CANCER AND BEYOND

Amplia Therapeutics Limited (“ATX” or “the Company”) releases its Bioshares Biotech Summit Presentation which Managing Director Dr Chris Burns will present at the Bioshares Biotech Summit in Queenstown, NZ today.

This ASX announcement was approved and authorised for release by the Managing Director of Amplia Therapeutics

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 411 235 692

U.S. Contact:

Robert Giordano
[rjgiordano@ggrouplifesc](mailto:rjgiordano@ggrouplifesciences.com)

first-line patients. The trial has achieved its desired outcome in achieving a response rate of 36%, superior to chemotherapy alone as reported for the benchmark MPACT study. A median Overall Survival (mOS) of 11.1 months has been reported along with an unprecedented complete response rate of 7.8%. A second trial (AMPLICITY) is being run at sites in Australia investigating the combination of narmafotinib with the chemotherapy mFOLFIRINOX in advanced pancreatic cancer patients, and a third trial in ovarian cancer (the PRROSE trial) is scheduled to begin recruiting later this year. A new trial, exploring the combination of narmafotinib with next-generation kRAS G12C inhibitor olomorasib in second-line NSCLC, is planned to start late 2026.

